| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 600838 | Colloids and Surfaces B: Biointerfaces | 2012 | 6 Pages |
Since its discovery the therapeutic use of the pancreatic hormone amylin has been limited due to its poor water solubility and propensity for amyloid aggregation. We have entrapped the human amylin protein in polymeric nanoparticles, using a single emulsion–solvent evaporation method and investigated its effectiveness in the controlled release of the peptide. Typical preparations composed of poly-ɛ-caprolactone had a mean particle size of approximately 200 nm, low polydispersity index, high protein entrapment efficiency (80%) and process yield (90%), and spherical and smooth surfaces. These nanoparticles presented a controlled release in vitro for approximately 240 h. Pharmacological evaluation in vivo by subcutaneous administration in fasting mice demonstrated the bioactivity and effectiveness of the released human amylin, resulting in reduced glycemia lasting for at least 36 h. These features indicate the potential for the use of a confined particulate system in the therapeutic controlled and sustained release of human amylin.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slideHighlights► Polymeric particles are considered for the entrapment of human amylin. ► Amylin-loaded particles are produced by simple emulsion and solvent evaporation. ► In vitro assays shows a sustained kinetic release of human amylin. ► Released amylin is bioactive.
